Concepedia

Author

Elmar A. Joura

Medical University of ViennaORCID

Also Known As

E A Joura, E Joura, E. A. Joura, E. Joura, E.A. Joura, ELMAR JOURA, Elmar A Joura, Elmar A. Joura, Elmar Armin Joura, Elmar Joura

235

Publications

10.8K

Citations

45

H-Index

92

Concepts

All Affiliations

Medical University of ViennaComprehensive Cancer Center ViennaRoyal Women's HospitalThe University of MelbourneMerck & Co., Inc., Rahway, NJ, USA (United States)
EA

About

Elmar A. Joura is an author at Medical University of Vienna specializing in medicine, obstetrics, and human papillomavirus vaccines.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

27

40

3.8K

2

Public Health

15

16

1.4K

3

Health Sciences

1

1

11

4

Allergy

1

1

105

5

Anesthesia

1

1

33

Elmar A. Joura

×

90

Publications

9.7K

Citations

41

H-Index

YearCitations

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

Elmar A. Joura, Anna R. Giuliano, Ole‐Erik Iversen,

New England Journal of Medicine

2015

1.4K

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years

Darron R. Brown, Susanne K. Kjær, Kristján Sigurðsson,

The Journal of Infectious Diseases

2009

627

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

Elmar A. Joura, Sepp Leodolter, Mauricio Hernández‐Ávila,

The Lancet

2007

576

Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women

Nubia Muñóz, Susanne K. Kjær, Kristján Sigurðsson,

JNCI Journal of the National Cancer Institute

2010

562

Natural History of Genital Warts: Analysis of the Placebo Arm of 2 Randomized Phase III Trials of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine

Suzanne M. Garland, Marc Steben, Heather L. Sings,

The Journal of Infectious Diseases

2009

520

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial

Warner K. Huh, Elmar A. Joura, Anna R. Giuliano,

The Lancet

2017

448

Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva

Silvia de Sanjosé, Laia Alemany, Jaume Ordï,

European Journal of Cancer

2013

381

A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions

Susanne K. Kjær, Kristján Sigurðsson, Ole‐Erik Iversen,

Cancer Prevention Research

2009

324

Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data

Elmar A. Joura, Suzanne M. Garland, Jorma Paavonen,

BMJ

2012

312

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16–26 Years

Cosette M. Wheeler, Susanne K. Kjær, Kristján Sigurðsson,

The Journal of Infectious Diseases

2009

241

Page 1